Group 1 - The company has expanded its partnership with AFT Pharmaceuticals Limited to commercialize BRIMOCHOL PF in Singapore [1] - A strategic partnership has been established with Santen Pharmaceutical Co., Ltd. to commercialize the product in Vietnam [1] - AFT and Santen have been granted exclusive distribution rights for BRIMOCHOL PF in their respective markets, highlighting the company's commitment to global expansion [1] Group 2 - BRIMOCHOL PF is a potential therapy for correcting near vision loss due to presbyopia, acquired through a partnership with Tenpoint Therapeutics, Ltd. [2] - Tenpoint is a global biotechnology company developing breakthrough therapies to restore vision in aging eyes [2] - The FDA has accepted the new drug application for BRIMOCHOL PF, with a review deadline set for January 28, 2026 [2]

Group 1 - The company has expanded its partnership agreement with AFT Pharmaceuticals Limited to commercialize BRIMOCHOL™ PF in Singapore [1] - The company has also established a strategic partnership with Santen Pharmaceutical Co., Ltd. to commercialize the product in Vietnam [1] - AFT and Santen have been granted exclusive distribution rights for BRIMOCHOL™ PF in their respective markets, highlighting the company's commitment to global expansion [1] Group 2 - BRIMOCHOL™ PF is a potential therapy for correcting near vision loss due to presbyopia, acquired through a partnership with Tenpoint Therapeutics, Ltd. [2] - Tenpoint announced that the FDA has accepted the new drug application for BRIMOCHOL™ PF, with a review deadline set for January 28, 2026 [2] - The FDA has established a Prescription Drug User Fee Act (PDUFA) date for the drug, indicating progress towards commercialization [2]

Group 1 - The company has expanded its partnership agreement with AFT Pharmaceuticals Limited to commercialize BRIMOCHOL™PF in Singapore [1] - A strategic partnership has been established with Santen Pharmaceutical Co., Ltd. to commercialize BRIMOCHOL™PF in Vietnam [1] - AFT and Santen are the seventh and eighth commercialization partners for BRIMOCHOL™PF, indicating the company's commitment to global expansion [1] Group 2 - BRIMOCHOL™PF is a potential therapy for correcting near vision loss due to presbyopia, acquired as a core asset through a partnership with Tenpoint [2] - Tenpoint is a global biotechnology company developing breakthrough therapies to restore vision in aging eyes [2] - The FDA has accepted the new drug application for BRIMOCHOL™PF, with a review deadline set for January 28, 2026 [2]

Group 1 - The company has expanded its partnership agreement with AFT Pharmaceuticals Limited to commercialize BRIMOCHOL PF in Singapore [1] - The company has established a strategic partnership with Santen Pharmaceutical Co., Ltd. to commercialize BRIMOCHOL PF in Vietnam [1] - AFT and Santen have been granted exclusive distribution rights for BRIMOCHOL PF in their respective markets, marking them as the seventh and eighth commercialization partners for the product [1] Group 2 - BRIMOCHOL PF is a potential therapy for correcting near vision loss due to presbyopia, acquired as a core asset through a partnership with Tenpoint Therapeutics, Ltd. [2] - Tenpoint is a global biotechnology company developing breakthrough therapies to restore vision in aging eyes [2] - The FDA has accepted the new drug application for BRIMOCHOL PF, with a review deadline set for January 28, 2026 [2]

（於英屬處女群島註冊成立並於開曼群島存續的有限公司） （股份代號：6622） 兆科眼科有限公司 自 願 性 公 告－ 透過與AFT及 千 寿 建 立 夥 伴 關 係，推 動 用 於 治 療 老 花 眼 的 BRIMOCHOL™ PF於新加坡及越南的商業化進程 本 公 告 乃 由 兆 科 眼 科 有 限 公 司（「本公司」）董 事 會（「董事會」）自 願 作 出。 本公司董事會欣然宣佈，本公司已擴大與領先健康護理產品製造商及分銷商AFT Pharmaceuticals Limited（「AFT」）的 夥 伴 協 議，以 於 新 加 坡 商 業 化BRIMOCHOL™ PF （「該產品」）。本 公 司 亦 已 與 亞 洲 領 先 眼 科 公 司 千 寿 製 薬 株 式 会 社（「千 寿」）建 立 策 略 夥 伴 關 係，以 於 越 南 商 業 化 該 產 品。 兆科分別授予AFT及 千 寿 於 新 加 坡 及 越 南 的 獨 家 分 銷 權，當 中 包 括 於 相 關 市 場 註 冊、進 口、推 廣、分 銷、營 銷 及 銷 售BRIMOCHOL™ PF的 權 利。透 過 該 等 協 議， AFT及千寿成為BRIM ...

（文章来源：每日经济新闻） 每经AI快讯，兆科眼科-B(06622.HK)午后涨超6%，截至发稿涨6.21%，报3.59港元，成交额328.27万港 元。 ...

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a significant stock increase of over 6% following the announcement of its registration application for a new treatment for myopia in children, which has been accepted for review by the Australian Therapeutic Goods Administration [1] Group 1: Company Announcement - On January 13, Zhaoke Ophthalmology-B announced that its registration application for the atropine sulfate eye drops (0.01% dosage, product code: NVK002) aimed at treating progressive myopia in children has been accepted for evaluation by the Australian Therapeutic Goods Administration [1] - The Therapeutic Goods Administration has officially informed the company that the application has passed the preliminary review and will undergo further evaluation [1] - The application is based on supportive results from the company's Phase III clinical trials [1] Group 2: Product Details - Atropine sulfate eye drops (NVK002) are a novel experimental topical ophthalmic solution designed to control the progression of myopia in children and adolescents [1] - The formulation of atropine sulfate eye drops (NVK002) is patented and successfully addresses the instability of low-concentration atropine, with intellectual property protection globally [1] - The product is preservative-free and is expected to have a shelf life of over 24 months [1]

Core Viewpoint - The company Zhaoke Ophthalmology-B (06622) has had its application for the registration of atropine sulfate eye drops accepted by the Australian Therapeutic Goods Administration, aimed at treating myopia progression in children [1] Group 1: Application Details - The application for the 0.01% atropine sulfate eye drops (product code: NVK002) was officially acknowledged by the Therapeutic Goods Administration on January 5, 2026, and has passed the preliminary review stage [1] - The application is supported by results from the company's Phase III clinical trials [1] Group 2: Product Information - Atropine sulfate eye drops (NVK002) are an experimental new topical ophthalmic solution designed to control myopia progression in children and adolescents [1] - The product features a patented formulation that successfully addresses the instability of low-concentration atropine, with global intellectual property protection [1] - The eye drops are preservative-free and are expected to have a shelf life of over 24 months [1] Group 3: Market Position - According to Zhi Shi Consulting, NVK002 is currently one of the most advanced atropine candidates globally for treating myopia progression, targeting a broad patient demographic of children and adolescents aged 3 to 17 [1]

Core Viewpoint - The company has submitted a registration application for its atropine eye drops (0.01% concentration, product code: NVK002) aimed at treating myopia progression in children, which has been accepted for review by the Australian Therapeutic Goods Administration [1] Group 1: Product Development - The application has passed preliminary review and will undergo further evaluation based on supportive results from the company's Phase III clinical trials [1] - NVK002 is a novel experimental topical eye solution designed to control myopia progression in children and adolescents [1] - The formulation of NVK002 addresses the instability of low-concentration atropine and is protected by intellectual property rights globally [1] Group 2: Market Position - NVK002 is currently one of the most advanced atropine candidates globally for treating myopia progression, targeting a broad patient group aged 3 to 17 years [1] - The product is preservative-free and is expected to have a shelf life of over 24 months [1]

Core Viewpoint - The company, Zhaoke Ophthalmology-B (06622.HK), has had its registration application for atropine sulfate eye drops (0.01% dosage, product code: NVK002) for treating myopia progression in children accepted by the Australian Therapeutic Goods Administration (TGA) [1] Group 1 - The TGA has officially notified the company that its application has passed the preliminary review and will undergo further evaluation [1] - The application is supported by results from the company's Phase III clinical trials [1] - NVK002 is a novel experimental topical eye solution designed to control myopia progression in children and adolescents [1] Group 2 - NVK002 features a patented formulation that successfully addresses the instability of low-concentration atropine, with intellectual property protection globally [1] - The eye drops are preservative-free and are expected to have a shelf life of over 24 months [1] - According to data from Zhi Shi Consulting, NVK002 is one of the most advanced atropine candidates globally for treating myopia progression, targeting a broad patient group aged 3 to 17 years [1]